Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2003 1
2009 1
2011 1
2012 1
2013 1
2014 2
2015 1
2017 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Current status of antibody therapy in ALL.
Ai J, Advani A. Ai J, et al. Br J Haematol. 2015 Feb;168(4):471-80. doi: 10.1111/bjh.13205. Epub 2014 Nov 10. Br J Haematol. 2015. PMID: 25382151 Free article. Review.
In this review, we will focus on the clinical application of such therapies in adult ALL, including the naked antibodies: Rituximab, Ofatumumab, Epratuzumab and Alemtuzumab; the immunotoxins: BL22 and Combotox; the immunoconjugates: inotuzumab and SAR 3419; as well as the …
In this review, we will focus on the clinical application of such therapies in adult ALL, including the naked antibodies: Rituximab, Ofatumu …
Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.
Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A. Barta SK, et al. Leuk Lymphoma. 2012 Oct;53(10):1999-2003. doi: 10.3109/10428194.2012.679267. Epub 2012 Apr 18. Leuk Lymphoma. 2012. PMID: 22448921 Free PMC article.
In our model the combination of both low- and high-dose Combotox and Ara-C resulted in significantly longer median survival. Sequential administration of Ara-C and Combotox, however, was shown to be superior to concurrent administration. ...
In our model the combination of both low- and high-dose Combotox and Ara-C resulted in significantly longer median survival. Sequenti …
A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia.
Herrera L, Bostrom B, Gore L, Sandler E, Lew G, Schlegel PG, Aquino V, Ghetie V, Vitetta ES, Schindler J. Herrera L, et al. J Pediatr Hematol Oncol. 2009 Dec;31(12):936-41. doi: 10.1097/MPH.0b013e3181bdf211. J Pediatr Hematol Oncol. 2009. PMID: 19875969 Clinical Trial.
Combotox has different toxicities and targets than chemotherapy and is, thus, a new candidate for the treatment of patients with relapsed ALL. Preclinical data have demonstrated which Combotox is effective in killing pre-B-ALL cell lines and cells from patients with …
Combotox has different toxicities and targets than chemotherapy and is, thus, a new candidate for the treatment of patients with rela …
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA. Messmann RA, et al. Clin Cancer Res. 2000 Apr;6(4):1302-13. Clin Cancer Res. 2000. PMID: 10778955 Clinical Trial.
Adult patients received a continuous infusion of Combotox at 10, 20, or 30 mg/m2/192 h. No intrapatient dose escalation was permitted. ...The maximum level of serum IT (Cmax) achieved in this group was 345 ng/ml of RFB4-dgA and 660 ng/ml of HD37-dgA (1005 ng/ml of Combo …
Adult patients received a continuous infusion of Combotox at 10, 20, or 30 mg/m2/192 h. No intrapatient dose escalation was permitted …
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.
Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A. Kyriakidis I, et al. J Fungi (Basel). 2021 Mar 5;7(3):186. doi: 10.3390/jof7030186. J Fungi (Basel). 2021. PMID: 33807678 Free PMC article. Review.
A detailed literature review until January 2021 was conducted regarding pediatric patient populations treated with agents that target CD2 (alefacept), CD3 (bispecific T-cell engager [BiTE] blinatumomab), CD19 (denintuzumab mafodotin, B43, BiTEs blinatumomab and DT2219ARL, the imm …
A detailed literature review until January 2021 was conducted regarding pediatric patient populations treated with agents that target CD2 (a …
A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.
Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S, Braunchweig I, Barta S, Ghetie V, Vitetta E, Verma A. Schindler J, et al. Br J Haematol. 2011 Aug;154(4):471-6. doi: 10.1111/j.1365-2141.2011.08762.x. Epub 2011 Jul 7. Br J Haematol. 2011. PMID: 21732928 Free PMC article. Clinical Trial.
Pre-clinical data demonstrated that Combotox was effective in killing both pre-B-ALL cell lines and cells from patients with pre-B ALL. ...All patients with peripheral blasts experienced decreased blast counts following the administration of Combotox. Thus, Combo …
Pre-clinical data demonstrated that Combotox was effective in killing both pre-B-ALL cell lines and cells from patients with pre-B AL …
Linked-in: design and efficacy of antibody drug conjugates in oncology.
Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK. Feld J, et al. Oncotarget. 2013 Mar;4(3):397-412. doi: 10.18632/oncotarget.924. Oncotarget. 2013. PMID: 23651630 Free PMC article.
Brentuximab vedotin is approved for use in Hodgkin's lymphoma and Trastuzumab emtansine is approved for breast cancer. Combotox, Inotuzumab Ozogamicin, and Moxetumomab Pasudotox are in various stages of clinical development and are showing significant efficacy in lymphoid …
Brentuximab vedotin is approved for use in Hodgkin's lymphoma and Trastuzumab emtansine is approved for breast cancer. Combotox, Inot …
Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
Herrera L, Farah RA, Pellegrini VA, Aquino DB, Sandler ES, Buchanan GR, Vitetta ES. Herrera L, et al. Leukemia. 2000 May;14(5):853-8. doi: 10.1038/sj.leu.2401779. Leukemia. 2000. PMID: 10803517
Because of the encouraging performance of these ITs in phase I trials, we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal feeder …
Because of the encouraging performance of these ITs in phase I trials, we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and …
12 results